Literature DB >> 15899217

[Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy].

Jose M Fernández-Cebrián1, Peter Vorwald Kuborn, Mar Pardo de Lama, Alfonso Sanjuanbenito Dehesa, Manuel Nevado Santos, Pedro A Pacheco Martínez, Beatriz Fernández-Escudero.   

Abstract

Colorectal cancer is one of the best studied of all malignant diseases in terms of genetics and/or molecular prognostic factors. These factors, and relationships with prognosis, may have important implications especially in the design of surgical and adjuvant chemo-radiotherapy options. However, the true prognostic significance of all known factors has yet to be realised. We have reviewed the literature with specific focus on the role of molecular markers involved in prognosis and the prediction of response to adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899217     DOI: 10.1007/bf02708742

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  76 in total

Review 1.  The epidermal growth factor receptor as a target for cancer therapy.

Authors:  J Mendelsohn
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

Review 2.  Molecular prognostics in colorectal cancer.

Authors:  Morton S Kahlenberg; John M Sullivan; Diana Dickson Witmer; Nicholas J Petrelli
Journal:  Surg Oncol       Date:  2003-11       Impact factor: 3.279

3.  Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients.

Authors:  L E Harrison; J G Guillem; P Paty; A M Cohen
Journal:  J Am Coll Surg       Date:  1997-07       Impact factor: 6.113

Review 4.  Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.

Authors:  B Van Triest; G J Peters
Journal:  Oncology       Date:  1999-10       Impact factor: 2.935

Review 5.  Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?

Authors:  F Graziano; S Cascinu
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

6.  Allelic loss of chromosome 18q and prognosis in colorectal cancer.

Authors:  J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

7.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Authors:  H E Mulcahy; M J Duffy; D Gibbons; P McCarthy; N A Parfrey; D P O'Donoghue; K Sheahan
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

8.  The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival.

Authors:  B R Dix; P Robbins; R Soong; D Jenner; A K House; B J Iacopetta
Journal:  Int J Cancer       Date:  1994-12-15       Impact factor: 7.396

9.  Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.

Authors:  R A Graham; S Wang; P J Catalano; D G Haller
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

10.  Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma.

Authors:  E W Kay; H Mulcahy; C B Walsh; M Leader; D O'Donoghue
Journal:  Histopathology       Date:  1994-11       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.